Frontlight ResearchEarly access
Taking people in DenmarkPhase 3
Tests lomustine with or without bevacizumab in recurrent glioblastoma
Compares lomustine alone with lomustine plus bevacizumab in adults with returning glioblastoma.
Key facts
- Who runs it
- Rigshospitalet
- Where
- Aalborg, Aarhus N, Copenhagen Oe, and Odense C, DenmarkSee the 4 sites
- Registry title
- A randomized phase III trial with lomustine versus lomustine and bevacizumab for patients with recurrent glioblastoma
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 168 people, planned
- Started
- 3 Feb 2025
- Expected to end
- 1 Dec 2026
- Type of study
- Interventional
- Record updated
- 13 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose glioblastoma has come back after first treatment with radiotherapy and temozolomide chemotherapy (the STUPP regimen). It compares lomustine alone with lomustine plus bevacizumab.
- Age
- Older than 18 years
- Sex
- All sexes
- Disease stage
- Glioblastoma confirmed under the microscope, coming back for the first time after radiotherapy with temozolomide chemotherapy (STUPP regimen). In case of early progression, at least 3 months after radiotherapy ended and at least 4 weeks after adjuvant chemotherapy.
- Earlier treatment
- Must have had the STUPP regimen. No more than one line of chemotherapy. Must not have had any treatment for the recurrence, including temozolomide again, or any drug aimed at the VEGF pathway.
Main reasons for not taking part
- Any earlier treatment for the recurrent glioblastoma, including temozolomide again
- Earlier use of a drug aimed at the VEGF pathway
- Medicines that could affect the results, such as immunosuppressive drugs (corticosteroids are allowed)
- Another cancer now or within the past 5 years, except treated basal or squamous cell skin cancer or cervical carcinoma in situ
- Medical, social or physical conditions that could get in the way of information or follow-up
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Signed informed consent • Histological verified glioblastoma • Recurrent GBM, previously treated according the STUPP regimen • No more than one line of chemotherapy (concurrent and adjuvant temozolomide based chemotherapy including in combination with another investigational agent is considered one line of chemotherapy). • PS 0-1 • Age > 18 • Expected survival > 3 months • First progression after RT concurrent/adjuvant chemotherapy (STUPPS regimen). In case of early progression, then at least 3 months after termination of radiotherapy and at least 4 weeks after adjuvant chemotherapy. • No more than one line of chemotherapy
Who cannot take part
- Previous therapy of recurrent GBM including temozolomide reinduction. • Previous use of biological drug targeting the VEGF-signaling pathway • Concurrent use of medication that can affect the interpretation of the results from the study, e.g. use of immunosuppressive drugs, except corticosteroids • Conditions (medical, social or physical) that may compromise proper information and/or follow-up • Other concurrent or previous cancer within 5 years, except adequately treated basal or squamous cell skin cancer, or cervical carcinoma in situ
Where in Denmark
- Aalborg University HospitalAalborg, DenmarkTaking people
- Aarhus University HospitalAarhus N, DenmarkTaking people
- Copenhagen University HospitalCopenhagen Oe, DenmarkTaking people
- Odense University HospitalOdense C, DenmarkTaking people
About the trial
What the trial wants to find out
The primary endpoint is overall survival
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- A randomized phase III trial with lomustine versus lomustine and bevacizumab for patients with recurrent glioblastoma
- Plain-language title
- Tests lomustine with or without bevacizumab in recurrent glioblastomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 13 January 2025